Home » NEUROBIOLOGICAL TECHNOLOGIES BEGINS XERECEPT TRIALS
NEUROBIOLOGICAL TECHNOLOGIES BEGINS XERECEPT TRIALS
Neurobiological Technologies announced the enrollment of the first patients in an open-label, extended-use study of Xerecept (hCRF). This study is open to all patients who participate in one of the two ongoing, blinded, Phase III trials designed to determine the dexamethasone-sparing effects of hCRF in brain tumor patients being treated for peritumoral brain edema.
This extended-use program will collect safety information and allow the treating physicians to attempt a maximum dexamethasone reduction and possible elimination altogether. Xerecept will be provided to patients until either the drug becomes commercially available or NTI research in this indication is discontinued.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May